NCT00674752

A Polysomnographic Study Of Single-Dose Gabapentin In Transient Insomnia

A Randomized, Double-Blind, Single-Dose, Placebo-Controlled, Multicenter, Polysomnographic Study Of Gabapentin 250 mg And 500 mg In Transient Insomnia Induced By A Sleep Phase Advance

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 377 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the effect of gabapentin on polysomnographic assessments in transient insomnia induced by a sleep phase advance.

Conditions

• Transient Insomnia

Interventions

Type	Name	Description
DRUG	Gabapentin	Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
DRUG	Gabapentin	Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
DRUG	Placebo	Matched placebo oral capsule 30 minutes prior to bedtime

Timeline

• Start date: 2006-03-01
• Completion: 2006-08-01
• First posted: 2008-05-08
• Last updated: 2021-02-02

Locations

4 sites across 1 country: United States